Galena Pharma +30% after presentation of positive data for GALE-301 (E39)

|By:, SA News Editor

"This final data from our early stage clinical trial demonstrates that GALE-301 is well tolerated and we were able to obtain statistically significant disease free survival in a small number of patients treated with the optimal dose,” says Chief Medical Officer Bijan Nejadnik.

Full details here

GALE +30.65% premarket